Trials / Terminated
TerminatedNCT03833427
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
A Phase 1b Multi-center Clinical Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety, pharmacokinetics, and efficacy of escalating doses of selumetinib (MK-5618) in combination with intravenous (IV) pembrolizumab (MK-3475) for participants with advanced / metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selumetinib | Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1\&2 of each 3-week treatment cycle. |
| DRUG | Pembrolizumab | Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle. |
Timeline
- Start date
- 2019-03-18
- Primary completion
- 2022-06-28
- Completion
- 2022-06-28
- First posted
- 2019-02-07
- Last updated
- 2024-11-07
- Results posted
- 2024-10-30
Locations
6 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03833427. Inclusion in this directory is not an endorsement.